• In late May 2026, Revolution Medicines reported detailed Phase 3 RASolute 302 data showing its oral RAS(ON) inhibitor daraxonrasib achieved statistically significant overall and progression-free survival benefits over standard chemotherapy in previously treated metastatic pancreatic cancer, with a manageable safety profile.
• The results, presented at ASCO 2026 and published in The New England Journal of Medicine, position daraxonrasib as a potential first-in-class option for RAS-driven pancreatic tumors with or without identified RAS mutations, addressing one of oncology’s most lethal and treatment-resistant cancers.
• We’ll now look at how these Phase 3 survival benefits in metastatic pancreatic cancer may reshape Revolution Medicines’ existing investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Revolution Medicines Investment Narrative Recap

To own Revolution Medicines, you need to believe its RAS(ON) pipeline can translate into approved drugs that justify today’s valuation despite zero revenue and heavy cash burn. The strong Phase 3 RASolute 302 survival data reinforces the near term regulatory catalyst around daraxonrasib in metastatic pancreatic cancer, but does not remove the key risk that an expensive, single theme pipeline must still clear multiple future clinical and commercial hurdles.

Among recent announcements, the FDA’s safe to proceed decision for expanded access to daraxonrasib in metastatic pancreatic cancer is especially relevant here. It shows regulators are already engaging with the program around real world use, which could matter for how quickly RASolute 302 data moves into potential filings and, eventually, how investors weigh upcoming readouts from the broader late stage RAS(ON) portfolio.

Yet against this progress, investors still need to be aware that Revolution Medicines remains pre revenue with GAAP operating expenses guided to US$1.6b to US$1.7b in 2026...

Revolution Medicines' narrative projects $1.0 billion revenue and $148.6 million earnings by 2029. This implies earnings would need to increase by about $1.3 billion from -$1.1 billion today.

Uncover how Revolution Medicines' forecasts yield a $133.70 fair value, a 10% downside to its current price.

Exploring Other Perspectives

Before this data, the most optimistic analysts were already modeling about US$2.1b of revenue and US$424.4m of earnings by 2029, so if you share that view you are effectively embracing a far more optimistic read on RAS(ON) uptake than consensus, while newer results like RASolute 302 may still reshape both those bullish forecasts and the risk that large, event driven trials slip or underdeliver.

Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Revolution Medicines research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Revolution Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revolution Medicines' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.